UNSPSC 51293604: Azepindole

This classification denotes an antidepressant agent with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BB6FW9T8J, chemically known as 2,3,4,5-tetrahydro-1h-(1,4)diazepino(1,2-a)indol but generally known as azepindole, which bears US NIH Compound Identifier 33471. European Medicines Agency schedules Azepindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05652MIG.

UNSPSC 51293604 Azepindole is a Commodity code that appears to have minimal recent state and local procurement activity aligned with its narrow pharmaceutical scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB 60459723LAS—is actually soliciting naloxone and safe drug deactivation systems for community health initiatives, not azepindole specifically. The mismatch suggests either a coding error in how the opportunity was tagged or that azepindole procurement under this code does not materialize frequently in state and local markets. Azepindole, as a pharmaceutical active ingredient, would typically appear in solicitations for finished medications or specialized chemical products rather than as a standalone procurement line item.

The Seminole County opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB required electronic bid submission through the county's e-Procurement Portal, E-Verify compliance, drug-free workplace certification, and standard insurance coverage. The contract carried a two-year initial term with a one-year renewal option and a three-month probationary period. Beyond this single record, the code shows no other recent state or local solicitations, indicating limited current market activity for azepindole procurement at the state and local level. Given the misalignment between the code's pharmaceutical scope and the naloxone-focused opportunity, the code does not present a clear pursuit opportunity in state and local contracting right now.